Raymond James & Associates’s Ascendis Pharma ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $538K | Sell |
3,601
-534
| -13% | -$79.7K | ﹤0.01% | 3051 |
|
|
2024
Q2 | $564K | Buy |
4,135
+3
| +0.1% | +$409 | ﹤0.01% | 2977 |
|
|
2024
Q1 | $625K | Buy |
4,132
+820
| +25% | +$124K | ﹤0.01% | 2897 |
|
|
2023
Q4 | $417K | Sell |
3,312
-43
| -1% | -$5.42K | ﹤0.01% | 3045 |
|
|
2023
Q3 | $314K | Sell |
3,355
-177
| -5% | -$16.6K | ﹤0.01% | 3170 |
|
|
2023
Q2 | $315K | Sell |
3,532
-49
| -1% | -$4.37K | ﹤0.01% | 3205 |
|
|
2023
Q1 | $384K | Buy |
3,581
+120
| +3% | +$12.9K | ﹤0.01% | 3052 |
|
|
2022
Q4 | $423K | Sell |
3,461
-1,019
| -23% | -$124K | ﹤0.01% | 2992 |
|
|
2022
Q3 | $463K | Sell |
4,480
-236
| -5% | -$24.4K | ﹤0.01% | 2908 |
|
|
2022
Q2 | $438K | Sell |
4,716
-218
| -4% | -$20.2K | ﹤0.01% | 2983 |
|
|
2022
Q1 | $579K | Sell |
4,934
-25,008
| -84% | -$2.93M | ﹤0.01% | 2972 |
|
|
2021
Q4 | $4.03M | Buy |
29,942
+1,398
| +5% | +$188K | ﹤0.01% | 1691 |
|
|
2021
Q3 | $4.55M | Buy |
28,544
+2,557
| +10% | +$408K | ﹤0.01% | 1555 |
|
|
2021
Q2 | $3.42M | Buy |
25,987
+1,884
| +8% | +$248K | ﹤0.01% | 1750 |
|
|
2021
Q1 | $3.11M | Buy |
24,103
+2,942
| +14% | +$379K | ﹤0.01% | 1733 |
|
|
2020
Q4 | $3.53M | Buy |
21,161
+532
| +3% | +$88.7K | ﹤0.01% | 1532 |
|
|
2020
Q3 | $3.18M | Buy |
20,629
+19,057
| +1,212% | +$2.94M | ﹤0.01% | 1474 |
|
|
2020
Q2 | $232K | Buy |
+1,572
| New | +$232K | ﹤0.01% | 3029 |
|
|
2020
Q1 | – | Sell |
-1,567
| Closed | -$218K | – | 3404 |
|
|
2019
Q4 | $218K | Buy |
+1,567
| New | +$218K | ﹤0.01% | 3266 |
|
|
2019
Q2 | – | Sell |
-2,895
| Closed | -$341K | – | 3512 |
|
|
2019
Q1 | $341K | Buy |
+2,895
| New | +$341K | ﹤0.01% | 2896 |
|